Peptide name : p28

Source/Organism : Pseudomonas aeruginosa

Linear/Cyclic : Linear

Chirality : L

Peptide length: 28

C-terminal modification: Linear

N-terminal modification : Free

Non-natural peptide information:

Assay type : MTT assay

Assay time : 24-h

Activity : IC50 ~ 150 μg/ml

Cell line : CT-26

Cancer type : Colorectal Cancer

Other activity : Antitumor

Amino acid composition bar chart :

Molecular mass : 2914.1787 Dalton

Aliphatic index : 0.732

Instability index : -6.1571

Hydrophobicity (GRAVY) : -0.371

Isoelectric point : 4.05

Charge (pH 7) : -4.233

Aromaticity : 3.571

Molar extinction coefficient (cysteine, cystine): (0, 0)

Hydrophobic/hydrophilic ratio : 1

hydrophobic moment : 0.4324

Missing amino acid : C,E,F,H,I,N,R,W

Most occurring amino acid : D

Most occurring amino acid frequency : 6

Least occurring amino acid : Q

Least occurring amino acid frequency : 1

Secondary structure fraction (Helix, Turn, Sheet): (35., 42., 28.)

SMILES Notation: CSCC[C@H](NC(=O)CNC(=O)[C@H](CC(=O)O)NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCSC)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(C)C)[C@@H](C)O)C(C)C)C(C)C)[C@@H](C)O)C(=O)N[C@@H](C)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CC(=O)O)C(=O)O

1 : Yaghoubi A, et al. Anticancer activity of Pseudomonas aeruginosa derived peptide with iRGD in colon cancer therapy. Iran J Basic Med Sci. 2023; 26:768-776. doi: 10.22038/IJBMS.2023.68331.14913

Paper title : Anticancer activity of Pseudomonas aeruginosa derived peptide with iRGD in colon cancer therapy.

Doi : https://doi.org/10.22038/IJBMS.2023.68331.14913

Abstract : OBJECTIVES: Colon cancer is well-known as a life-threatening disease. Since the current treatment modalities for this type of cancer are powerful yet face some limitations, finding novel treatments is required to achieve better outcomes with fewer side effects. Here we investigated the therapeutic potential of Azurin-p28 alone or along with iRGD (Ac-CRGDKGPDC-amide) as a tumor-penetrating peptide and 5-fluorouracil (5-FU) for colon cancer. MATERIALS AND METHODS: Inhibitory effect of p28 with or without iRGD/5-FU was studied in CT26 and HT29, as well as the xenograft animal model of cancer. The effect of p28 alone or along with iRGD/5-FU on cell migration, apoptotic activity, and cell cycle of the cell lines was assessed. Level of the BAX and BCL2 genes, tumor suppressor genes [(p53 and collagen type-Iα1 (COL1A1), collagen type-Iα2 (COL1A2)] were assessed by quantitative RT-PCR. RESULTS: These findings show that using p28 with or without iRGD and 5-FU raised the level of p53 and BAX but decreased BCL2, compared with control and 5-FU groups in tissues of the tumor, which result in raising the apoptosis. CONCLUSION: It seems that p28 may be used as a new therapeutic approach in colon cancer therapy that can enhance the anti-tumor effect of 5-FU.